No profile data available.
Insulet Corporation (PODD) is a healthcare company in the IV treatment equipment industry, based in Acton, United States, with about 5,400 full-time employees.
It reported revenue of $2.71 billion for fiscal year 2025, up 30.7% from fiscal year 2024, and net income of $247.10 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $801.70 million, up 23.5% from a year before. United States was its largest region in fiscal year 2025, with 72% of revenue. Its market capitalization was $9.38 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally.
Insulet reported $2.71 billion in revenue for fiscal year 2025, up 30.7% from $2.07 billion in fiscal year 2024. In Q2 2026 revenue was $801.70 million.
United States: 72% of revenue by region in fiscal year 2025, followed by International (28%).
$9.38 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (IV treatment equipment) include ICU Medical, Inc. (ICUI), Tandem Diabetes Care, Inc. (TNDM), Iradimed Corporation (IRMD), Beta Bionics, Inc. (BBNX).